게놈 편집 시장 : 기술별, 치료 영역별, 전달 방법별, 용도별, 최종사용자별 - 세계 시장 예측(2026-2032년)

The Genome Editing Market is projected to grow by USD 21.71 billion at a CAGR of 10.96% by 2032.

Genome editing has moved from a research breakthrough to a clinical and commercial capability for therapeutic innovators. CRISPR-Cas systems, zinc finger nucleases, TALENs, base editing, prime editing, and RNA-guided epigenetic editing are reshaping how pharmaceutical and biotechnology developers address monogenic disease, oncology, immunology, infectious disease, ophthalmology, and rare disorders.

The sector gained major clinical validation when CRISPR-based exa-cel received landmark regulatory authorizations for sickle cell disease and transfusion-dependent beta thalassemia in 2023 and 2024, including approvals by the U.S. FDA, the U.K. MHRA, the European Commission, and other national authorities. For therapy developers, the genome editing landscape is now defined by clinical differentiation, delivery efficiency, off-target risk management, scalable manufacturing, ethical governance, and durable evidence generation.

Transformative Shifts in the Therapeutic Landscape

The genome editing landscape is shifting from first-generation nuclease cutting toward higher-precision modalities. Base editing enables single-letter DNA changes without double-strand breaks, while prime editing broadens programmable correction potential by supporting targeted insertions, deletions, and substitutions. These approaches are accelerating pipeline expansion across hematology, liver disease, ophthalmology, oncology, immune-mediated disorders, and inherited metabolic conditions.

Commercial strategy is also changing. Ex vivo editing benefits from controlled manufacturing and established cell therapy infrastructure, while in vivo genome editing depends on safer delivery through lipid nanoparticles, viral vectors, and tissue-targeted systems. Regulatory expectations increasingly emphasize long-term follow-up, validated off-target assays, transparent patient monitoring, product comparability, and risk-based assessment of permanent genomic changes.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding progress across the genome editing value chain. Machine learning models are used to design guide RNAs, predict on-target efficiency, assess off-target activity, optimize editor architecture, identify pathogenic variants, and prioritize targets with stronger disease relevance. Public advances in protein structure prediction, including AlphaFold-enabled biology, have also accelerated enzyme engineering, functional annotation, and target validation.

For therapeutic developers, AI reduces experimental search space but does not replace wet-lab validation. The strongest competitive advantage comes from combining high-quality genomic datasets, single-cell and multi-omics data, functional screens, clinically annotated cohorts, and rigorous bioinformatics with compliant model governance that supports reproducible, regulator-ready evidence.

Key Regional Insights for Genome Editing

North America remains a therapeutic genome editing leader due to deep biomedical funding, major academic medical centers, FDA experience in gene and cell therapy review, mature clinical trial infrastructure, and established GMP biomanufacturing capacity. Europe combines strong biomedical research with EMA oversight, national health technology assessment requirements, General Data Protection Regulation-driven data governance, and strict ethical expectations around germline editing. Asia-Pacific is advancing rapidly, led by China, Japan, South Korea, Australia, and India, with strong clinical research capacity, expanding precision medicine programs, and growing policy attention to biotechnology self-sufficiency.

Latin America is building relevance through Brazil and Mexico, especially in clinical research participation, public health genomics, and agricultural biotechnology spillovers. The Middle East is investing in genomic medicine through national programs in Saudi Arabia, the UAE, Qatar, and other Gulf states, strengthening sequencing infrastructure and specialty care pathways. Africa's opportunity is tied to inherited blood disorders, infectious disease, crop resilience, and capacity-building initiatives, although laboratory infrastructure, financing, and regulatory harmonization remain uneven across the region.

Key Group Insights Across Strategic Alliances

The G7 anchors much of the therapeutic genome editing ecosystem through public research funding, regulatory precedent, intellectual property generation, clinical trial density, and advanced biomanufacturing. The European Union plays a central role in harmonized medicines regulation, cross-border research governance, data protection, ethics oversight, and ongoing policy debates over new genomic techniques in agriculture and health. NATO economies increasingly view synthetic biology and genome editing through a dual-use and biosecurity lens, supporting stronger safeguards for sensitive research, biological data, and enabling technologies.

BRICS countries are important for scale, clinical recruitment, agricultural application, public health genomics, and cost-efficient R&D, with China, India, and Brazil particularly influential. ASEAN is emerging through biomedical research hubs in Singapore, Thailand, and Malaysia, while food security, aquaculture, and infectious disease priorities support broader regional relevance. The GCC is using national genomics initiatives, hospital modernization, and precision medicine programs to create demand for advanced diagnostics, cell therapies, rare disease management, and future genome editing partnerships.

Key Country Insights for Genome Editing Adoption

The United States leads in clinical translation, FDA precedents, venture-backed biotechnology, academic spinouts, and advanced cell and gene therapy manufacturing. Canada contributes strength in genomics, stem cell research, population health data, and clinical networks, while Mexico offers expanding trial capacity, cross-border healthcare relevance, and regional manufacturing potential. Brazil is the Latin American anchor for biotechnology oversight, research scale, agricultural biotechnology experience, and large patient population access.

In Europe, the United Kingdom remains influential through MHRA innovation pathways, national genomics infrastructure, and translational research networks, while Germany and France bring pharmaceutical depth, public research institutes, advanced engineering, and biomanufacturing capability. Italy and Spain support clinical research, rare disease networks, and hospital-based translational medicine, while Russia maintains scientific capacity in molecular biology and biotechnology despite geopolitical constraints. In Asia-Pacific, China is a major clinical research and manufacturing force, India is expanding genomics, bioeconomy policy, and gene editing applications for agriculture and health, Japan offers regenerative medicine expertise and a structured regulatory pathway for advanced therapies, Australia provides strong translational research and clinical trial quality, and South Korea brings advanced biopharma, digital health integration, and CDMO capabilities.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize indications where genome editing offers clear clinical superiority over existing therapy, such as one-time functional cures, durable remission, reduced treatment burden, or differentiated safety. Delivery strategy should be treated as a core platform asset, not a supporting technology, because tissue targeting, payload constraints, biodistribution, and immune response management often determine clinical feasibility.

Developers should invest early in off-target detection, long-term follow-up systems, scalable GMP manufacturing, payer evidence packages, patient access planning, and ethical review processes. Strategic partnerships with AI platform specialists, academic genome centers, CDMOs, clinical trial networks, and patient advocacy organizations can shorten development timelines while improving credibility with regulators, clinicians, and payers.

Research Methodology

This executive summary is grounded in secondary research from verified public sources, including regulatory agency releases, peer-reviewed literature, clinical trial registries, government policy documents, public health guidance, and technical publications on genome editing, gene therapy, and advanced therapeutics. Insights reflect documented milestones such as CRISPR therapeutic approvals, WHO governance recommendations, national regulatory frameworks, and peer-reviewed evidence on editing efficiency, delivery systems, and safety evaluation.

The analysis synthesizes technology adoption, regional readiness, clinical translation, manufacturing feasibility, policy signals, and ethical governance. No unsupported revenue estimates are used; emphasis is placed on validated developments, observable investment and research patterns, approved products, clinical-stage activity, public regulatory positions, and reproducible scientific evidence.

Conclusion

Genome editing is entering a more disciplined phase in which scientific novelty must translate into safe, durable, manufacturable, ethically governed, and reimbursable products. The first CRISPR therapy approvals proved that programmable editing can reach patients, but broader adoption will depend on delivery innovation, regulatory trust, manufacturing scale, long-term safety monitoring, and clinical evidence quality.

Therapeutic leaders that integrate AI-enabled design, robust validation, ethical governance, and global access strategy will be better positioned to build sustainable advantage. The next phase of genome editing will reward organizations that move beyond platform promise and demonstrate measurable patient outcomes across well-defined clinical settings.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Genome Editing Market, by Technology

• 7.1. Base Editing
  • 7.1.1. Adenine Base Editor
  • 7.1.2. Cytosine Base Editor
• 7.2. CRISPR
  • 7.2.1. Cas12
  • 7.2.2. Cas13
  • 7.2.3. Cas9
• 7.3. MegaTAL
• 7.4. Prime Editing
• 7.5. TALEN
• 7.6. ZFN

8. Genome Editing Market, by Therapeutic Area

• 8.1. Cardiology
• 8.2. Genetic Disorders
• 8.3. Infectious Diseases
• 8.4. Neurology
• 8.5. Oncology

9. Genome Editing Market, by Delivery Method

• 9.1. Nonviral
  • 9.1.1. Electroporation
  • 9.1.2. Lipid Nanoparticles
• 9.2. Physical Methods
  • 9.2.1. Gene Gun
  • 9.2.2. Microinjection
• 9.3. Viral Vector

10. Genome Editing Market, by Application

• 10.1. Agricultural
  • 10.1.1. Crop Improvement
  • 10.1.2. Livestock Improvement
• 10.2. Industrial Biotechnology
  • 10.2.1. Biofuels
  • 10.2.2. Biomanufacturing
• 10.3. Research
  • 10.3.1. Basic Research
  • 10.3.2. Drug Discovery
• 10.4. Therapeutics
  • 10.4.1. Cell Therapy
  • 10.4.2. Gene Therapy

11. Genome Editing Market, by End User

• 11.1. Academic Institutes
• 11.2. Contract Research Organizations
• 11.3. Pharmaceutical Biotech

12. Genome Editing Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Genome Editing Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Genome Editing Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Agilent Technologies, Inc.
• 16.2. AMS Biotechnology Ltd.
• 16.3. Arbor Biotechnologies Inc
• 16.4. Beam Therapeutics Inc.
• 16.5. Caribou Biosciences Inc.
• 16.6. Cellectis SA
• 16.7. Century Therapeutics Inc
• 16.8. Creative Biogene
• 16.9. CRISPR Therapeutics AG
• 16.10. Danaher Corporation
• 16.11. Editas Medicine Inc
• 16.12. GenScript
• 16.13. Gilead Sciences Inc
• 16.14. Horizon Discovery Group PLC
• 16.15. Intellia Therapeutics Inc
• 16.16. Lonza Group Ltd.
• 16.17. Mammoth Biosciences
• 16.18. Merck KGaA
• 16.19. Metagenomi
• 16.20. New England Biolabs, Inc.
• 16.21. OriGene Technologies, Inc.
• 16.22. Poseida Therapeutics Inc
• 16.23. Precision BioSciences Inc
• 16.24. Prime Medicine Inc
• 16.25. Regeneron Pharmaceuticals Inc
• 16.26. Sangamo Therapeutics Inc
• 16.27. Scribe Therapeutics
• 16.28. Synthego Corporation
• 16.29. Takara Bio Inc.
• 16.30. Tessera Therapeutics Inc
• 16.31. Thermo Fisher Scientific Inc
• 16.32. Vertex Pharmaceuticals Incorporated
• 16.33. Verve Therapeutics Inc